Zura Bio Limited (ZURA) is a clinical-stage, multi-asset immunology biotechnology company, not an exchange-traded fund. A review of seven recent, attributed analyst price targets produced a mean of roughly $17.71, rounded to a central target of $18. The individual figures are Wedbush ($22, October 2026), Piper Sandler ($26, October 2026), Guggenheim ($20, October 2026), Leerink Partners ($11, October 2026), Oppenheimer ($16, June 2026), Chardan Capital ($11, May 2026) and Clear Street ($18, December 2025), giving a low-to-high range of $11 to $26.
The wide range reflects genuinely different views on clinical-stage risk. Higher targets from Piper Sandler, Wedbush and Guggenheim emphasize the breadth of Zura Bio's pipeline and multiple upcoming data catalysts, while the lower Leerink and Chardan figures apply more conservative risk adjustments. Crucially, all seven targets were issued before Zura Bio disclosed that tibulizumab missed its primary endpoint in a Phase 2 hidradenitis suppurativa study, so they may be revised sharply lower. The $18 figure is a calculated mean of these targets, not an official published consensus.
Shares closed near $4.09 before the November 2026 trial disclosure and then fell roughly 68% in pre-market trading to about $1.30, according to Reuters, after tibulizumab failed to beat placebo on lesion-reduction endpoints. Even measured from the pre-announcement close of about $4.09, reaching $18 requires an upside of approximately 340% — a very large move. The company plans to discontinue tibulizumab development in hidradenitis suppurativa while continuing studies in systemic sclerosis (TibuSURE, data expected in the first half of 2027) and other inflammatory indications. A path back toward higher levels would likely require the systemic sclerosis program, crebankitug (ZB-168) in alopecia areata, or torudokimab to deliver positive data and restore investor confidence.
Before the trial news, the stock was already trading near the bottom of its 52-week range of $3.25 to $7.44 and below its 200-day moving average. The pre-market decline broke through that prior $3.25 floor, leaving earlier support levels far overhead. In a post-failure environment, psychological round numbers and any stabilization zone that forms after the gap down are more relevant references than the old range. The wide bid-ask spread and micro-cap status can amplify volatility in either direction.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts may use different assumptions, and the pending revisions make the current horizon uncertain. Investors should monitor whether analysts lower their targets in response to the HS failure, the systemic sclerosis (TibuSURE) readout expected in the first half of 2027, crebankitug and torudokimab development updates, cash burn and runway disclosures, and quarterly results. Regulatory decisions and the broader appetite for speculative biotechnology names will also matter.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-heavy name like Zura Bio, automated scanning can help traders spot shifting trends and monitor positions more efficiently than manual chart review. Traders can use the signals to discover new opportunities, track existing holdings, and react more quickly when technical conditions change. Explore the AI Daily Buy/Sell Signals to see how the system reads the current tape.
The $18 target is the average of seven pre-setback analyst price targets ranging from $11 to $26. After tibulizumab's Phase 2 hidradenitis suppurativa failure and the subsequent price collapse toward $1.30, the distance to $18 has widened dramatically, and the target itself is likely to be revised lower as analysts absorb the news. The strongest remaining supports are the diversified pipeline, the systemic sclerosis readout ahead, and a sizable cash balance, while the principal obstacles are the lead-program failure, probable target cuts, and high short interest. Reaching $18 would require a multi-year, multi-program turnaround rather than a single positive catalyst. Investors should focus on upcoming data readouts and analyst revisions rather than treating the $18 figure as a reliable forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ZURA has been closely correlated with ABEO. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if ZURA jumps, then ABEO could also see price increases.
| Ticker / NAME | Correlation To ZURA | 1D Price Change % | ||
|---|---|---|---|---|
| ZURA | 100% | +13.31% | ||
| ABEO - ZURA | 68% Closely correlated | -3.35% | ||
| ACAD - ZURA | 58% Loosely correlated | +10.79% | ||
| IONS - ZURA | 51% Loosely correlated | -9.06% | ||
| VIR - ZURA | 44% Loosely correlated | -3.63% | ||
| RCUS - ZURA | 42% Loosely correlated | -1.48% | ||
More | ||||